Comparative safety signal prioritization of CDK4/6 inhibitors in breast cancer: a FAERS pharmacovigilance, machine learning, and clinical contextualization study.

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Verzenio (abemaciclib) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42688497

Chang Su; Linlin Fan; Shaochun Liu; Wenhui Zhao; Xiaoxi Han; Yuhan Tang; Zhaoqi Zhang; Zhiqi Sui

Sep 4, 2026